8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 27, 2026·SEC
ALX Oncology Holdings Inc.(ALXO)Earnings, Financials & Key Ratios
ALXO•NASDAQ
$2.06
Price updated Jul 2, 2026
AboutALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$103M+27.0%
- Net Income-$102M+24.6%
- EPS (Diluted)-1.90+26.4%
- ROE-145.7%-63.9%
ALXO Price & Volume
ALX Oncology Holdings Inc. (ALXO) stock price & volume — 10-year historical chart
Loading chart...
ALXO Growth Metrics
ALX Oncology Holdings Inc. (ALXO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.2%
Return on Capital
10 Years-95.77%
5 Years-68.56%
3 Years-94.05%
Last Year-127.03%
ALXO Recent Earnings
ALX Oncology Holdings Inc. (ALXO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.17-13.3%
$0.15
Rev
—
—
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.42-10.5%
$0.38
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.41-10.8%
$0.37
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.49-6.5%
$0.46
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.17vs $0.15-13.3% | — |
| Q1 2026 | Feb 27, 2026 | $0.42vs $0.38-10.5% | — |
| Q4 2025 | Nov 7, 2025 | $0.41vs $0.37-10.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.49vs $0.46-6.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ALX Oncology Holdings Inc. (ALXO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.06 | $111.71M | -1.08 | — | — | -145.7% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $28.92 | $2.91B | -8.79 | -4.26% | -156.36% | -68.97% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $64.39 | $1.26B | -6.62 | -43.89% | -284.18% | -87% | — |
Compare ALXO vs Peers
ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALXO SEC Filings & Documents
ALX Oncology Holdings Inc. (ALXO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ALXO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALXO Frequently Asked Questions
ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ALXO profitable?
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $88.9M for fiscal year 2025.
Dividend & Returns
What is ALXO's return on equity?
ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -145.7%. Negative ROE indicates the company is unprofitable.
What is ALX Oncology Holdings Inc.'s free cash flow?
ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $78.3M in fiscal year 2025, likely due to heavy capital investments.